39.07

2.52% 0.98

After Hours: 41.37 2.30 +5.89%

Soleno Therapeutics Inc (SLNO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Soleno Therapeutics Inc stock is traded at $39.07, with a volume of 1.38M. It is up +2.52% in the last 24 hours and down -9.52% over the past month. Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Previous Close:

$38.09

Open:

$37.85

24h Volume:

1.38M

Relative Volume:

0.92

Market Cap:

$2.10B

Revenue:

Net Income/Loss:

$-38.99M

P/E Ratio:

-13.04

EPS:

-2.9966

Net Cash Flow:

$-24.94M

1W Performance:

-0.79%

1M Performance:

-9.52%

6M Performance:

-42.30%

1Y Performance:

-13.20%

1-Day Range:

$37.85

$39.07

1-Week Range:

$32.63

$41.62

52-Week Range:

$32.63

$90.32

Soleno Therapeutics Inc Stock (SLNO) Company Profile

Name

Soleno Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

650-213-8444

Address

100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA

Employee

152

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

SLNO's Discussions on Twitter

Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLNO Soleno Therapeutics Inc	39.07	2.05B	0	-38.99M	-24.94M	-2.9966
VRTX Vertex Pharmaceuticals Inc	496.83	121.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	781.67	81.49B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	766.92	47.74B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	332.76	43.93B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	316.99	35.67B	4.98B	69.60M	525.67M	0.5198

Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-25	Initiated	Wolfe Research	Outperform
Oct-07-25	Initiated	Goldman	Buy
Aug-20-25	Initiated	Wells Fargo	Overweight
Jun-23-25	Initiated	TD Cowen	Buy
Mar-05-25	Resumed	Stifel	Buy
Dec-02-24	Reiterated	Robert W. Baird	Outperform
Dec-02-24	Reiterated	Stifel	Buy
Sep-03-24	Initiated	H.C. Wainwright	Buy
May-10-24	Initiated	Robert W. Baird	Outperform
Feb-05-24	Initiated	Piper Sandler	Overweight
Jan-23-24	Initiated	Stifel	Buy
Nov-21-23	Resumed	Guggenheim	Buy
Sep-29-20	Initiated	Guggenheim	Buy
Jan-10-20	Initiated	Craig Hallum	Buy
Dec-23-19	Initiated	Oppenheimer	Outperform
Feb-13-18	Reiterated	Maxim Group	Buy

View All

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc Stock (SLNO) Company Profile

Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC

Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades

Soleno Therapeutics Inc Stock (SLNO) Latest News

Soleno Therapeutics (NASDAQ:SLNO) Given New $85.00 Price Target at TD Cowen - MarketBeat

Soleno Therapeutics stock hits 52-week low at 37.95 USD - Investing.com Nigeria

Soleno Therapeutics (NASDAQ:SLNO) Reaches New 1-Year LowShould You Sell? - MarketBeat

Soleno Therapeutics Names New Chief Financial Officer - marketscreener.com

Soleno Therapeutics stock hits 52-week low at 36.01 USD - Investing.com

Eli Lilly (LLY) Veteran Joins Soleno Therapeutics as CFO - GuruFocus

Soleno Therapeutics names Jennifer Fulk as CFO - Investing.com

Soleno Therapeutics Appoints Jennifer Fulk As Chief Financial Officer - Nasdaq

Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer - The Manila Times

Eli Lilly veteran Jennifer Fulk to lead finances at rare disease firm Soleno - Stock Titan

Soleno Therapeutics, Inc. Announces Chief Financial Officer Changes - marketscreener.com

Soleno Therapeutics Announces New Chief Financial Officer Appointment - TipRanks

Biopharmaceutical company Soleno Therapeutics recently announced a major personnel appointment - Bitget

Soleno Therapeutics Q4 Earnings Call Highlights - MarketBeat

Earnings call transcript: Soleno Therapeutics Q4 2025 earnings beat expectations By Investing.com - Investing.com Australia

SLNO: VYKAT XR achieved rapid adoption, strong revenue, and profitability in its first year post-launch - TradingView

Soleno (SLNO) Q4 2025 Earnings Call Transcript - AOL.com

Earnings call transcript: Soleno Therapeutics Q4 2025 earnings beat expectations - Investing.com

Soleno Therapeutics (NASDAQ:SLNO) Announces Earnings Results - MarketBeat

Earnings Flash (SLNO) Soleno Therapeutics, Inc. Reports Q4 Revenue $91.7M, vs. FactSet Est of $88.8M - marketscreener.com

Soleno Therapeutics Earnings Review: Q4 Summary - Benzinga

BRIEF-Soleno Therapeutics Q4 EPS USD 0.8 - TradingView

Soleno Therapeutics Reports Fourth Quarter and Full-Year - GlobeNewswire

Soleno Therapeutics faces earnings test as launch metrics scrutinized By Investing.com - Investing.com UK

Soleno Therapeutics faces earnings test as launch metrics scrutinized - Investing.com

Soleno Therapeutics to Announce Q4 Earnings on February 25 - Intellectia AI

What to Expect from Soleno Therapeutics's Earnings - Benzinga

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Biotech Contender with 184% Upside Potential - DirectorsTalk Interviews

Will Soleno Therapeutics Inc. benefit from sector rotationEarnings Recap Summary & Weekly High Potential Stock Alerts - mfd.ru

Avoro Capital Advisors LLC Increases Stake in Soleno Therapeutics Inc - GuruFocus

CenterBook Partners LP Acquires 38,282 Shares of Soleno Therapeutics, Inc. $SLNO - MarketBeat

Skandinaviska Enskilda Banken AB publ Increases Stock Holdings in Soleno Therapeutics, Inc. $SLNO - MarketBeat

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Soleno Therapeutics (NASDAQ:SLNO) Hits New 12-Month LowHere's Why - MarketBeat

Soleno Therapeutics (SLNO) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Readystate Asset Management LP Has $13.91 Million Holdings in Soleno Therapeutics, Inc. $SLNO - MarketBeat

Commit To Purchase Soleno Therapeutics At $25, Earn 17.8% Annualized Using Options - Nasdaq

Wellington Management Group LLP Increases Stake in Soleno Therap - GuruFocus

Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance - Finviz

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Biotech Firm Surges with 200% Upside Potential - DirectorsTalk Interviews

(SLNO) Risk Channels and Responsive Allocation - Stock Traders Daily

TimesSquare Capital Management LLC Has $25.52 Million Stake in Soleno Therapeutics, Inc. $SLNO - MarketBeat

Soleno Therapeutics Updates PWS Launch, Reimbursement Trends and EU Review at Guggenheim Summit - MarketBeat

Soleno Therapeutics stock hits 52-week low at 37.95 USD By Investing.com - Investing.com Australia

Soleno Therapeutics (NASDAQ:SLNO) Sets New 1-Year LowTime to Sell? - MarketBeat

Is Soleno Therapeutics Inc. currently under institutional pressure2025 Key Lessons & Intraday High Probability Alerts - mfd.ru

SLNO: Strong market uptake, stable safety, and robust reimbursement support ongoing growth - TradingView

Why is Soleno Therapeutics Inc. stock going downGap Up & Safe Entry Trade Reports - mfd.ru

Why Soleno Therapeutics Inc. (6XC) stock is listed among top recommendationsJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - mfd.ru

Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET - The Manila Times

Soleno Therapeutics to Report Fourth Quarter and Full-Year - GlobeNewswire

Soleno Therapeutics Inc Stock (SLNO) Financials Data

Revenue

Net Income

Cash Flow

EPS

Soleno Therapeutics Inc Stock (SLNO) Insider Trading

Similar to SLNO